GSA Capital Partners LLP Acquires New Position in Coherus Oncology, Inc. $CHRS

GSA Capital Partners LLP bought a new position in Coherus Oncology, Inc. (NASDAQ:CHRS) in the second quarter, according to its most recent filing with the SEC. The firm bought 379,355 shares of the biotechnology company’s stock, valued at approximately $531,000.

Other large investors also recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of Coherus Oncology during the second quarter worth $46,000. BNP Paribas Financial Markets increased its position in shares of Coherus Oncology by 108.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 13,832 shares during the period. Corient Private Wealth LLC lifted its position in Coherus Oncology by 20.0% during the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 10,000 shares during the period. Blair William & Co. IL acquired a new stake in Coherus Oncology during the 4th quarter worth about $27,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Coherus Oncology during the 1st quarter valued at about $60,000. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on CHRS shares. Guggenheim started coverage on Coherus Oncology in a report on Monday, May 11th. They issued a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Coherus Oncology in a research report on Friday, August 7th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.67.

Coherus Oncology Trading Down 0.8%

NASDAQ CHRS opened at $1.32 on Friday. Coherus Oncology, Inc. has a 1 year low of $1.06 and a 1 year high of $2.62. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.77 and a quick ratio of 1.70. The company has a market capitalization of $203.94 million, a PE ratio of -1.28 and a beta of 0.98. The company has a fifty day moving average of $1.41 and a 200 day moving average of $1.61.

Coherus Oncology (NASDAQ:CHRS) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.06. The company had revenue of $14.31 million for the quarter, compared to the consensus estimate of $14.41 million. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%. Research analysts forecast that Coherus Oncology, Inc. will post -0.88 earnings per share for the current year.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.